You are here: Home » 2021 » June » Archives for 7th

FXCM Pro partners with multi-asset trading platform Fortex

LONDON and SYDNEY, Australia and JOHANNESBURG, South Africa, June 07, 2021 (GLOBE NEWSWIRE) — FXCM, the leading international provider of online foreign exchange trading, CFD trading and related services, announced that FXCM Pro, the institutional arm of the business, is partnering with Fortex, a leading multi–asset trading technology platform.

The partnership between FXCM Pro and Fortex integrates FXCM Pro's liquidity with Fortex's XForce 2.0 platform. XForce 2.0 is a multi–asset trading platform that packs liquidity aggregation, order and risk management, MT4/5 Bridges, FIX API, hosting, and multiple trading GUI into one valued cloud native SaaS offering in NY4/LD4/HK1.

FXCM Pro will combine its world leading multi–asset trading technology solution with Fortex's market leading service, providing institutions and professional traders with a first–class trading experience and access to key industry platforms.

Daniel Chen, CEO and Co–founder at Fortex, commented: "Fortex specializes in helping enterprise clients innovate and re–orient their trading business to fuel continuous growth. From exchange products to FX/CFD to crypto derivatives, we discover deep values for our clients by leading changes and overcoming pain points, armed with superior computing power and data insights. Our team holds a client first, liquidity neutral and broker agnostic principle. FXCM Pro's transparent and pure agency model resonates with our core value. We are very excited to partner with FXCM Pro."

Mario Sanchez, Managing Director and Global Head of FXCM Pro Sales, commented: "FXCM Pro's liquidity management team continues to work hard to develop partnerships that will enhance execution and trading efficiency. Our latest partnership with Fortex provides us with an additional channel, and we are both aligned in our strategy of easing connection and offering customized trading solutions. Through this partnership, we are ensuring that FXCM Pro's liquidity is easily accessible to a wide pool of brokers, hedge funds and professional traders."

Disclaimers:

This communication is intended for institutional and professional clients only.

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Trading Forex/CFDs on margin carries a high level of risk and may not be suitable for all investors.

Leverage can work against you. The products are intended for retail, professional and eligible counterparty clients. Retail clients who maintain account(s) with Forex Capital Markets Limited (“FXCM LTD”), could sustain a total loss of deposited funds but are not subject to subsequent payment obligations beyond the deposited funds but professional clients and eligible counterparty clients could sustain losses in excess of deposits. Prior to trading any products offered by FXCM LTD or other firms within the FXCM group of companies [collectively the “FXCM Group”], carefully consider your financial situation and experience level. If you decide to trade products offered by FXCM Australia Pty. Limited ("FXCM AU") (AFSL 309763), you must read and understand the Financial Services Guide, Product Disclosure Statement, and Terms of Business. Our FX and CFD prices are set by us, are not made on an Exchange and are not governed under the Financial Advisory and Intermediary Services Act. The FXCM Group may provide general commentary, which is not intended as investment advice and must not be construed as such. Seek advice from a separate financial advisor. The FXCM Group assumes no liability for errors, inaccuracies or omissions; does not warrant the accuracy, completeness of information, text, graphics, links or other items contained within these materials. Read and understand the Terms and Conditions on the FXCM Group's websites prior to taking further action.

About Fortex

Founded in 1997, Fortex Technologies aims to revolutionize trading with its powerful, neutral, multi–asset trading platform focused on the FX, equities, and crypto markets. Fortex's XForce solution, ECN, MT4/5 bridges, infrastructure hosting and more are used by regional banks, hedge funds, asset managers, broker dealers and professional traders around the world to enhance liquidity access, improve execution workflows and support sophisticated trading strategies. For more information about Fortex, please visit www.Fortex.com

Media contact:

Chatsworth Communications
+44 (0) 20 7440 9780
[email protected]


GLOBENEWSWIRE (Distribution ID 8249909)

Sophi.io Wins Two INMA Global Media Awards

TORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Sophi.io, The Globe and Mail's artificial intelligence–powered optimization and prediction platform, was announced as a winner of the International News Media Association (INMA) Global Media Awards in two categories, Best Use of Data to Automate or Personalize, and Best in Show for North America.

"The INMA Global Media Awards focus on excellence across all areas of the media business," said Phillip Crawley, Publisher and CEO of The Globe and Mail. "I'm particularly pleased that Sophi's fully dynamic, real–time, personalized paywall won in two categories, and that Sophi's ground–breaking automated print laydown technology was nominated for its use with Naviga and Agderposten."

Sophi also took second place in the categories of Best Initiative to Acquire Subscribers and Best Use of Data to Drive Subscriptions, Content, or Product Design and was shortlisted as a finalist in the following categories: Best Initiative to Register Users, and Best Product and Tech Innovation.

This year's competition drew 644 entries from 212 news brands in 37 countries. The judges were 44 global media experts focused on breakthrough results, unique concepts, strong creativity, innovative thinking, and winner synergies across platforms.

"Great use of data with huge impact. Personalizing paywalls is key for success in the digital subscription business for news media. This entry presents more evidence why this is true," one judge said about the paywall technology. "Their development of user– and content–propensity models is a best practice that others can learn from," said another judge.

Another judge remarked: "Incredible Artificial Intelligence–driven personalization, and perfect embracing of the need to insert data–science talent into a news organization. Excellent impact and numbers.”

Sophi's fully dynamic, personalized, real–time paywall uses natural language processing (NLP) to analyze both content and user behaviour to determine when to ask a reader for money or an email address, and when to leave them alone. It can optimize for multiple outcomes simultaneously (such as different bundles or price points) and also works well in cold–start situations.

Sophi is an AI platform that helps publishers identify their most valuable content and leverage it to achieve key business goals, such as maximizing subscriptions. Publishers on four continents now use Sophi's AI/ML technology to power paywall decisions, website automation and print automation.

Sophi's automated print laydown solution, which powers Naviga Publisher, earned an honourable mention in the Best Product and Tech Innovation category. An INMA judge commented: "Sophi – as the first of its kind – is a great example of an automated print laydown solution. Amazing to see that the work of the editor is reduced only to the selection of the content. The automation of up to 80% of newspapers' editorial pages could be a game–changer of the print industry.”

Last year, Sophi also won the Online Journalism Award (OJA) for Technical Innovation in the Service of Digital Journalism, handed out by the Online News Association (ONA), and both the World Digital Media Award and the North American Digital Media Award awarded by The World Association of News Publishers (WAN–IFRA) in the category of Best Digital News Start–up.

About Sophi.io
Sophi.io (https://www.sophi.io) was developed by The Globe and Mail to help content publishers make important strategic and tactical decisions. It is a suite of AI and ML–powered optimization and prediction tools that includes Sophi Site Automation and Sophi Dynamic Paywall as well as Sophi Analytics, a decision–support system for content publishers. Sophi is designed to improve the metrics that matter most to your business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.


GLOBENEWSWIRE (Distribution ID 8249606)

Carnrite to Moderate Executive Panels at Upcoming Reuters Events

DUBAI, United Arab Emirates, June 07, 2021 (GLOBE NEWSWIRE) — Alan "Al' Carnrite, President & CEO of management consultancy The Carnrite Group, has been tasked with moderating two expert panels at back–to–back Reuters Events in June. The first event is Data–Driven Oil & Gas 2021 (June 14–15), which will be followed by Global Energy Transition (June 21–25).

At the Data Driven Oil & Gas 2021 conference, Carnrite is moderating the panel entitled "Digital Transformation in Action: Upstream Operations." The discussion will be live on June 14th for attendees of the conference. The panelists are top executives from Shell, Eni, ADNOC and OAG Analytics, who will share examples of digital transformation in action and discuss digital strategies in place to reduce cost, lower carbon emissions, improve efficiency and reduce downtime.

For the second conference, Global Energy Transition, Al Carnrite will lead a discussion about the challenges and opportunities facing companies as they navigate the Energy Transition. "Name Your Price" will explore topics such as incentivizing investments required to achieve commitments made in the Paris Agreement, the implications of putting a price on carbon and the potential for global cooperation. Carnrite will facilitate the conversation between leaders from Persefoni, the Energy Transitions Commission and EDP.

When asked about the upcoming conferences, Carnrite said: "I'm excited about the opportunity to moderate these panels. Both subjects are timely and complex, and Reuters Events has done a great job assembling a knowledgeable group of panelists with diverse experiences and perspectives."

About The Carnrite Group

Carnrite is a management consultancy focused primarily on the energy, industrial and private equity sectors. From offices in the USA, UK, and the UAE, Carnrite deploys its unique combination of consulting and industry expertise to projects globally. Carnrite is a dedicated, practical business partner with the ability to implement complex change. Areas of expertise include strategy and transaction support, business transformation, human capital, the Energy Transition and Digital Transformation. To further augment its offerings Carnrite has assembled an innovative ecosystem of strategic partners that spans leading technologies and adjacent consulting services. Carnrite recognises that its clients face difficult business decisions "" its mission is to make it easier for them.


GLOBENEWSWIRE (Distribution ID 8249762)

Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints

Mont–Saint–Guibert, Belgium "" 7 June 2021, 7:00 am CET / 1:00 am ET "" Nyxoah SA (Euronext Brussels: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the BETTER SLEEP trial reached its primary safety and performance endpoints.

The BETTER SLEEP trial was designed to assess the long–term safety and performance of the Genio bilateral hypoglossal nerve stimulation system (the "Genio system") in 42 adult OSA patients with and without Complete Concentric Collapse (CCC) of the soft palate.

Top–line results from the BETTER SLEEP study showed:

  • A statistically significant mean reduction in Apnea Hypopnea Index (AHI) from baseline to six months post implantation in the whole cohort (CCC and non–CCC patients)
  • A statistically significant mean reduction in AHI from baseline to six months post implantation in the CCC patient subgroup
  • 42.9% of the study population had CCC

The Company expects to announce additional data with respect to the study as further analyses are conducted.

Dr. Richard Lewis, MBBS, FRACS, Principal Investigator of the BETTER SLEEP study, from Royal Perth Hospital and the University of Western Australia commented: "The top–line results of the BETTER SLEEP study are extremely encouraging. The most impressive aspect of the results is the responder rate of the CCC patient subgroup. These patients are excluded from unilateral hypoglossal nerve stimulation, but the BETTER SLEEP results showed a significant reduction in AHI in these patients following treatment with the Genio system, which is the first device designed to deliver bilateral stimulation of the hypoglossal nerve. Overall, we have achieved a very high responder rate in both CCC and non–CCC patients, and the treatment with the Genio system was well tolerated. We look forward to publishing this data in a leading medical journal."

Olivier Taelman, CEO of Nyxoah, stated: "We are excited by the top–line data, with the primary performance and safety endpoints met, supporting our belief that the Genio system's bilateral stimulation of the hypoglossal nerve, has the potential to provide positive clinical outcomes for patients with CCC. We already engaged with the EU Notified Body to review these study data, with the goal of expanding the CE–marked indication to include CCC patients. In parallel, we plan to initiate dialogue with the FDA to further discuss the Genio system as a potential treatment option for patients with CCC." Mr. Taelman continued, "Additionally, we observed a 70% responder rate in the non–CCC patient subgroup based on the Sher criteria, which strengthens our confidence in ongoing study outcomes."

About BETTER SLEEP Trial
BilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea, or BETTER SLEEP, is a multicenter, prospective, open–label, two–group clinical trial, designed to assess the safety and performance of the Genio system for the treatment of OSA in adult patients with and without CCC. The BETTER SLEEP trial includes a subgroup of CCC patients who are currently contraindicated for unilateral hypoglossal nerve stimulation. The trial was authorized by the Australian and New Zealand regulatory authorities and is being conducted in nine local medical centers. The primary safety endpoint was the incidence of device–related serious adverse events six months post–implantation. The primary performance endpoint was the change in the AHI score from baseline to six months post–implantation measured by counting the number of events (apnea or hypopnea) that occur per hour collected during an overnight sleep study. Patients with moderate to severe AHI scores between 15 and 65 and aged between 21 and 75 years were eligible for enrollment if they failed, refused, or did not tolerate PAP treatment. Patients with a body mass index above 32 kg/m were excluded.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah's lead solution is the Genio system, a CE–marked, patient–centered, minimally invasive, next generation hypoglossal neurostimulation therapy for treatment of moderate to severe OSA. OSA is the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for potential CE–mark indication expansion, the DREAM IDE pivotal study for potential FDA approval and the post–marketing EliSA study in Europe to evaluate the long–term safety and efficacy of the Genio system.

For more information, please visit www.nyxoah.com.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal
law to investigational use in the United States.

Forward–Looking Statements
This press release includes certain disclosures that contain "forward–looking statements," including, without limitation, statements regarding Nyxoah's expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; and the utility of prior clinical data, including data from the BETTER SLEEP study, in potentially obtaining FDA approval of the Genio system. Forward–looking statements are based on Nyxoah's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ. Forward–looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
[email protected]
+32 10 22 23 55

Gilmartin Group
Vivian Cervantes
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1000509219)